Investor Presentaiton

Eurofins is expanding its global offering in non-invasive prenatal testing (NIPT) MAGENOMA® Molecular Genetics Laboratories Group * eurofins life codexx In September 2017, Eurofins' Genoma introduced GeneSafe™, the first non-invasive prenatal test that screens for both de novo (non-inherited gene mutations) and inherited single-gene disorders. " GeneSafe™ detects over 40 severe genetic disorders: that may occur in absence of any family history of the condition. GeneSafe™ is the first NIPT to detect disorders that are increasingly prevalent with advanced paternal age: later-stage parenthood is becoming increasingly common. GeneSafe TM is more advanced than other NIPTs currently available: identifying fetal conditions that could be missed by traditional prenatal testing. Many disorders screened with GeneSafe™: GeneSafe Are not typically associated with abnormal prenatal ultrasound findings. " May not be evident until late second/third trimester or even after delivery. In July 2017, Eurofins acquired a majority stake in LifeCodexx AG, Europe's first NIPT provider and one of the most innovative NIPT players. LifeCodexx has been developing innovative and clinically validated tests since 2010. LifeCodexx's PrenaTestⓇ was Europe's first NIPT: for the determination of the most common chromosomal disorders in unborn children. This was a substantial development that changed prenatal diagnostics considerably. LifeCodexx, following a positive CE marking, began rolling-out their unique qPCR-based NIPT capabilities in December 2016: leading to increased cost- efficiency and rapid turnaround time, another significant innovative step in the NIPT field. Eurofins NIPTs are very reliable (>99% of conclusive results), fast (turnaround time under 2 weeks, qPCR assays only take 2-3 days) and simple (only a small blood sample required). Eurofins is the first provider to offer the aforementioned novel NIPT tests, GeneSafe TM and qPCR-based NIPT, to the market. 60

View entire presentation